Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-01-29
2010-06-01
Jiang, Shaojia Anna (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S276000
Reexamination Certificate
active
07727995
ABSTRACT:
Composition and methods are disclosed that include a synergistic combination of an inhibitor of Herpes simplex virus thymidine kinase, and an antiherpes substance.
REFERENCES:
patent: 5137724 (1992-08-01), Balzarini et al.
patent: 5646155 (1997-07-01), Wright
patent: 5879700 (1999-03-01), Hostetler
patent: 6015573 (2000-01-01), Hostetler
Naesens et. al (Herpes, 8(1), 2001.
Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 10th Edition, McGraw-Hill Medical Publishing Division, 2001, pp. 54-56.
Gilbert et al., “Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms” (2002) vol. 5 pp. 88-114.
Nutter et al., “Demonstration of Viral Thymidine Kinase Inhibitor and it's Effect on Deoxynucleotide Metabloism in Cells Infected with Herpes Simplex Virus”, Antimicrobial Agents and Chemotherapy, vol. 31, No. 3, pp. 368-374, Mar. 1987.
Klein et al., “Effect of a Thymidine Kinase Inhibitor (L-653,180) on Antiviral Treatment of Experimental Herpes Simplex Virus Infection in Mice”, Anitviral Research, 14, pp. 207-214, 1990.
Manikowski et al., “Inhibition of Herpes Simplex Virus Thymidine Kinases by 2-Phenylamino-6-oxopurines and Related Compounds: Structure-Activity Relationships and Antiherpetic Activity in Vivo”, J. Med. Chem., vol. 48, pp. 3919-3929, 2005.
Naesens et al., “Recent Developments in Herpesvirus Therapy”, Herpes vol. 8, No. 1, 2001.
Xu et al., “Synethesis, Properties and Pharmacokinetic Studies of N2-Phenylguanine Derivatives as Inhhibitors of Herpes Simplex Virus Thymidine Kinases”, J. Med. Chem., vol. 38, pp. 49-57, 1995.
Klein et al., “Effect of a thymidine kinase inhibitor (L-653,180) on antiviral treatment of experimental herpes simplex virus infection in mice”, Antiviral Research, vol. 14, pp. 207-214, 1990.
Reardon et al., “Herpes Simplex Virus Type I DNA Polymerase Mechanism of Inhibition by Acyclovir Triphosphate*”, The Journal of Biological Chemistry, vol. 264, No. 13, pp. 7405-7411, May 1989.
Ashton et al., “A Potent. Selective, Non-Substrate Inhibitor Of HSV-1 Thymidine Kinase: (±)-9-[I(Z)-2-(Hydroxymethyl)Cyclohexyl]Methyl]Guanine And Related Compounds”, Nucleosides, Nucleotides, vol. 8, pp. 1157-1158, 1989.
Nutter et al., “Demonstration of Viral Thymidine Kinase Inhibitor and Its Effect on Deoxynucleotide Metabolism in Cells Infected with Herpes Simplex Virus”, Antimicrobial Agents and Chemotherapy, vol. 31, No. 3, Mar. 1987.
Fish & Richardson P.C.
Jiang Shaojia Anna
Olson Eric S
University of Massachusetts
LandOfFree
Antiherpes drug combinations does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antiherpes drug combinations, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antiherpes drug combinations will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4161824